OnKure Therapeutics, Inc. (NASDAQ:OKUR – Get Free Report) traded up 1.3% on Tuesday . The company traded as high as $4.70 and last traded at $4.56. 347,142 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 564,816 shares. The stock had previously closed at $4.50.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on OKUR shares. HC Wainwright reduced their price target on shares of OnKure Therapeutics from $34.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, March 16th. Wall Street Zen raised OnKure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Weiss Ratings raised shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Finally, JonesTrading lowered shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $27.00.
Read Our Latest Stock Analysis on OnKure Therapeutics
OnKure Therapeutics Price Performance
OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.37). As a group, equities research analysts forecast that OnKure Therapeutics, Inc. will post -3.19 EPS for the current year.
Institutional Trading of OnKure Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vivo Capital LLC purchased a new stake in shares of OnKure Therapeutics during the first quarter valued at $7,981,000. ADAR1 Capital Management LLC boosted its stake in shares of OnKure Therapeutics by 140.1% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,434,941 shares of the company’s stock worth $10,081,000 after buying an additional 1,420,783 shares during the last quarter. Rosalind Advisors Inc. purchased a new stake in OnKure Therapeutics during the fourth quarter valued at $2,118,000. Shay Capital LLC boosted its position in OnKure Therapeutics by 417.8% in the second quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock worth $1,869,000 after purchasing an additional 631,008 shares during the last quarter. Finally, Prosight Management LP grew its position in OnKure Therapeutics by 204.9% during the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock valued at $2,369,000 after buying an additional 548,950 shares during the period. 90.98% of the stock is currently owned by institutional investors.
OnKure Therapeutics Company Profile
OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.
The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.
Read More
- Five stocks we like better than OnKure Therapeutics
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
